Figure 6.

FGF inhibition attenuates tumorigenesis in-vivo and in-vitro. (A) The FGFR inhibitor AZD4547 reduced HepG2 cells proliferation induced by medium of heated human immortalized hepatocytes (43 °C for 5 min followed by 3h at 37 °C) (n = 3 each arm, Total N = 12). (B) images of the MDR2-KO liver treated with FGFR inhibitor or oil, arrows mark some of the tumors. (C) FGFR inhibitor reduced number of liver tumors 1 month post-RFA treatment in 7 months (n = 17) and 12 months MDR2-KO mice (7–11 animals/arm, Total N = 34). (D) qRT-PCR on the peri-ablational rim 24 h post liver RFA of MDR2-KO mice with FGFR inhibitor and its control (oil) shows reduced levels of FGFs post inhibitor administration. α-SMA showed increased levels post-RFA in the oil administration that are reduced by FGFR inhibitor (N = 15). For all experiments p-values calculated by two tailed t-test *p < 0.05, **p < 0.01.